IBRX
ImmunityBio Inc.
Company Overview
| Mkt Cap | $7.89B | Price | $7.10 |
| Volume | 11.83M | Change | -2.81% |
| P/E Ratio | -19.1 | Open | $7.27 |
| Revenue | $14.7M | Prev Close | $7.30 |
| Net Income | $-413.6M | 52W Range | $1.83 - $12.43 |
| Div Yield | N/A | Target | $14.80 |
| Overall | 39 | Value | 40 |
| Quality | 28 | Technical | 50 |
No chart data available
About ImmunityBio Inc.
ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies. The company's platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.
Latest News
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26%
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IBRX | $7.10 | -2.8% | 11.83M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |